Delivery Vehicles for Small Interfering RNA In Vivo
- 1 February 2008
- journal article
- review article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 19 (2), 125-132
- https://doi.org/10.1089/hum.2008.928
Abstract
RNA interference (RNAi) as a mechanism to selectively silence messenger mRNA (mRNA) expression has revolutionized the biological sciences. With the identification and sequencing of the entire human genome complete, RNAi can be harnessed to rapidly develop novel drugs against any disease target. The ability of synthetic small interfering RNA (siRNA) to potently, but reversibly, silence genes in vivo, has made them particularly well suited as a drug therapeutic. Development of therapeutics using siRNA has advanced rapidly, with five different clinical trials ongoing and several more poised to enter the clinic in the coming years. Although challenges remain, delivery represents the main hurdle for faster and broader development of siRNA therapeutics. In this review, a summary of the advances in in vivo siRNA delivery is presented and discussed. Multiple different delivery approaches have demonstrated success ranging from the relative simplicity of direct local administration of saline-formulated siRNA, to liposome- and polymer-based nanoparticle approaches, to conjugation and complexation approaches. For siRNA therapeutics to achieve their full potential as a revolutionary class of drug molecules, multiple distinct delivery technologies will likely be needed, with selection of delivery approach being dependent on the nature of the clinical indication, the route of administration to be used, and the cell types to be targeted. Lastly, a status report on current clinical trials using siRNA is given.Keywords
This publication has 48 references indexed in Scilit:
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007
- Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathwayNature, 2007
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1Proceedings of the National Academy of Sciences, 2007
- Hyperoxia causes angiopoietin 2–mediated acute lung injury and necrotic cell deathNature Medicine, 2006
- Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma TherapyClinical Cancer Research, 2006
- Aptamer mediated siRNA deliveryNucleic Acids Research, 2006
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006